Takeaway

• Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use was associated with a significantly reduced risk for atherosclerotic cardiovascular disease (ASCVD), hospitalisation for heart failure (HHF), and renal events compared with dipeptidyl peptidase-4 inhibitors (DPP4is) among patients with type 2 diabetes without baseline ASCVD, HF, or chronic kidney disease.
• No significant differences were...